Eli Lilly sues Strive and Empower as FDA lifts tirzepatide shortage status
Eli Lilly is escalating its legal push to protect the exclusivity of its high-profile weight-loss and diabetes drugs, ...
Hims & Hers shares rise as company adds new weight-loss medications to platform
Zepbound, Mounjaro and liraglutide are part of the class of weight loss medications called GLP-1s, which have exploded in ...
Eli Lilly Vs. Novo Nordisk: Which Is The Better Bargain For Investors
Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain ...
Where Will Eli Lilly Be in 1 Year?
Lately, however, Eli Lilly's stock has cooled. Shares have been essentially flat since July 2024. The market for GLP-1 ...
Eli Lilly launches weight-loss drug Mounjaro in India, beats Novo Nordisk to major market
Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...
Eli Lilly weight loss therapy added to Hims & Hers platform (update)
Hims & Hers Health (NYSE:HIMS) stock gains as the company adds Eli Lilly's (LLY) weight loss therapy tirzepatide & generic ...
Hims & Hers to Sell Lilly's Weight-Loss Drug on Its Telehealth Platform
(Reuters) -Telehealth firm Hims & Hers Health said on Monday it plans to sell Eli Lilly's weight-loss drug Zepbound on its ...
Eli Lilly is coming after makers of copycat versions of Zepbound
Eli Lilly (LLY) is taking legal action against makers of off-brand versions of its blockbuster diabetes and weight-loss drugs ...